公开(公告)号：US20240156940A1

公开(公告)日：2024-05-16

申请号：US18394555

申请日：2023-12-22

申请人： GeoVax, Inc.

发明人： Harriet Robinson ,  Arban Domi ,  Michael Hellerstein

IPC分类号： A61K39/12 ,  C12N15/86 ,  C12N15/863

CPC分类号： A61K39/12 ,  C12N15/86 ,  C12N15/863 ,  A61K2039/5256 ,  C12N2710/24141 ,  C12N2710/24143 ,  C12N2760/10034 ,  C12N2760/14134 ,  C12N2760/14234

摘要： The compositions and methods are described for generating an immune response to a hemorrhagic fever virus such as ebolavirus, Marburgvirus, or arenavirus. The compositions and methods described herein relate to a modified vaccinia Ankara (MVA) vector encoding one or more viral antigens for generating a protective immune response to a member of genus Ebolavirus (such as a member of species Zaire ebolavirus), a member of genus Marburgvirus (such as a member of species Marburg marburgvirus), or a member of genus Arenavirus (such as a member of species Lassa virus) in the subject to which the vector is administered. The compositions and methods of the present invention are useful both prophylactically and therapeutically and may be used to prevent and/or treat an infection caused by ebolavirus, Marburgvirus, or arenavirus.

公开(公告)号：US11739302B2

公开(公告)日：2023-08-29

申请号：US16926803

申请日：2020-07-13

申请人： Shenzhen Hua Yao Kang Ming Biopharmaceutical Co., Ltd.

发明人： Ming Yuan

IPC分类号： C12N15/863 ,  C12N7/00 ,  A61K9/00 ,  A61K39/395 ,  G01N33/50 ,  C12Q1/02 ,  G01N33/574 ,  A61K31/513 ,  A61K31/519 ,  A61K31/7068 ,  A61K35/768 ,  A61P35/00 ,  A61K31/505 ,  A61K38/20 ,  A61K47/00 ,  A61K39/00

CPC分类号： C12N7/00 ,  A61K9/0014 ,  A61K9/0019 ,  A61K9/0043 ,  A61K9/0053 ,  A61K31/505 ,  A61K31/513 ,  A61K31/519 ,  A61K31/7068 ,  A61K35/768 ,  A61K38/208 ,  A61K38/2013 ,  A61K39/3955 ,  A61K47/00 ,  A61P35/00 ,  C12Q1/02 ,  G01N33/5005 ,  G01N33/57407 ,  A61K2039/5252 ,  C12N2710/24121 ,  C12N2710/24132

摘要： An engineered vaccinia virus, a pharmaceutical composition containing the same, and methods for use in treating a subject in need using the same are provided. The engineered vaccinia virus includes a mutated viral sequence and a heterologous sequence. The mutated viral sequence is used for selective replication in tumor cells and/or activation of immune cells. The heterologous sequence encodes an immune co-stimulatory pathway activating molecule, immunomodulator gene, a truncated viral envelope gene, and/or a tumor suppressor. The heterologous sequence is stably incorporated into the genome of the engineered vaccinia virus. The pharmaceutical composition includes an effective amount of the engineered vaccinia virus and a pharmaceutical acceptable vehicle. The methods for use in treating the subject in need include administering the engineered vaccinia virus to the subject.

公开(公告)号：US11207400B2

公开(公告)日：2021-12-28

申请号：US16593658

申请日：2019-10-04

申请人： Janssen Vaccines & Prevention B.V. ,  Beth Israel Deaconess Medical Center, Inc.

发明人： Dan Barouch ,  Johanna Schuitemaker ,  Maria Grazia Pau ,  Danielle Van Manen ,  Frank Tomaka ,  Jennifer Anne Hendriks

IPC分类号： C12N15/861 ,  C12N15/863 ,  A61K39/21 ,  C07K14/005 ,  C12N15/86 ,  A61K39/12 ,  C12N7/00 ,  A61K39/00

摘要： Compositions, vaccines and methods for inducing an immunity, including a protective immunity, against Human Immunodeficiency Virus (HIV) infection are described. Heterologous vaccine combinations of one or more adenovirus 26 vectors using for priming immunization and an isolated HIV antigenic polypeptide in combination with one or more MVA vectors for boosting immunization induced strong protective immunity against infections by one or multiple clades of HIV.

公开(公告)号：US10561721B2

公开(公告)日：2020-02-18

申请号：US15507975

申请日：2015-09-03

申请人： Bavarian Nordic A/S ,  Janssen Vaccines & Prevention B.V. ,  The United States of America, as represented by The Secretary, Department of Health and Human Services

发明人： Ariane Volkmann ,  Robin Steigerwald ,  Ulrike Dirmeier ,  Maria Grazia Pau ,  Benoit Christophe Stephan Callendret ,  Lucy A. Ward

IPC分类号： A61K39/12 ,  C12N15/863 ,  C12N15/861 ,  C12N7/00 ,  A61K39/00

摘要： The present invention provides compositions, vaccines and methods for inducing protective immunity against filovirus infection, particularly protective immunity against infection of one or more subtypes of Ebola viruses and Marburg virus.

公开(公告)号：US10160979B2

公开(公告)日：2018-12-25

申请号：US15524879

申请日：2015-11-11

申请人： TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE ,  NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION ,  THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE

发明人： Michinori Kohara ,  Yasuhiro Yasutomi ,  Yumiko Shiogama

IPC分类号： A61K39/00 ,  A61K39/12 ,  A61K39/275 ,  A01N63/00 ,  A61K48/00 ,  C12N15/863 ,  A61K39/29 ,  A61K31/7088 ,  A61K35/76 ,  C12N15/09 ,  G01N33/576 ,  C07H21/00

摘要： The present invention can induce stronger cellular immunity to hepatitis C and provide a treatment means and a prevention means that are effective in completely eliminating the hepatitis C virus (HCV). Provided is a pharmaceutical composition for the treatment and/or prevention of hepatitis C, said composition comprising a recombinant vaccinia virus (a) and a recombinant vector (b) and characterized in that after one of the recombinant vaccinia virus (a) and the recombinant vector (b) is administered for initial immunity, the other is administered for additional immunity. The recombinant vaccinia virus (a) contains an expression promoter and all or a portion of the cDNA of the HCV genome. The recombinant vector (b) contains an expression promoter and all or a portion of the cDNA of the HCV (where the cDNA contained in the recombinant vector (b) has a different base sequence than that included in the recombinant vaccinia virus (a)).

公开(公告)号：US09879231B2

公开(公告)日：2018-01-30

申请号：US14837382

申请日：2015-08-27

申请人： The United States of America, as represented by the Secretary, Dept. of Health and Human Services

发明人： Bernard Moss ,  Linda S. Wyatt ,  Patricia L. Earl

IPC分类号： C12N7/00 ,  C07K14/005 ,  C12N15/86 ,  C12N15/863 ,  A61K39/285 ,  A61K39/00

CPC分类号： C12N7/00 ,  A61K39/285 ,  A61K2039/5256 ,  C07K14/005 ,  C12N15/86 ,  C12N15/8636 ,  C12N2710/24121 ,  C12N2710/24133 ,  C12N2710/24143 ,  C12N2710/24152 ,  C12N2740/16122 ,  C12N2740/16222

摘要： The present invention relates to recombinant modified vaccinia Ankara (MVA) virus containing restructured sites useful for the integration of heterologous nucleic acid sequences into an intergenic region (IGR) of the virus genome, where the IGR is located between two adjacent, essential open reading frames (ORFs) of the vaccinia virus genome, wherein the adjacent essential ORFs are non-adjacent in a parental MVA virus used to construct the recombinant MVA virus, and to related nucleic acid constructs useful for inserting heterologous DNA into the genome of a vaccinia virus, and further to the use of the disclosed viruses as a medicine or vaccine.

公开(公告)号：US20170211098A1

公开(公告)日：2017-07-27

申请号：US15399588

申请日：2017-01-05

申请人： BAVARIAN NORDIC A/S

发明人： Robin STEIGERWALD

IPC分类号： C12N15/863

CPC分类号： C12N15/8636 ,  C12N15/86 ,  C12N2710/24134 ,  C12N2710/24143 ,  C12N2710/24151 ,  C12N2740/11022 ,  C12N2760/14122 ,  C12N2799/02 ,  C12N2800/22

摘要： The invention relates to vectors comprising two or more homologous nucleotide sequences and methods for generating them. The invention concerns substituting bases in the homologous nucleotide sequences with different bases that do not alter the encoded amino acid sequence. The invention allows for the reduction of intramolecular recombination between homologous nucleotide sequences, in particular in mammalian cells. The invention further relates to nucleotide sequences containing substituted bases.

公开(公告)号：US09567606B2

公开(公告)日：2017-02-14

申请号：US13767603

申请日：2013-02-14

申请人： Teshome Mebatsion ,  Jules Maarten Minke ,  Frederic David

发明人： Teshome Mebatsion ,  Jules Maarten Minke ,  Frederic David

IPC分类号： C12N15/63 ,  C12N15/86 ,  C12N15/863 ,  A61K39/008 ,  A61K39/12 ,  A61K39/39 ,  A61K39/00

CPC分类号： C12N15/86 ,  A61K39/008 ,  A61K39/12 ,  A61K39/205 ,  A61K39/39 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/552 ,  A61K2039/55516 ,  C12N15/8633 ,  C12N2710/24043 ,  C12N2760/20134

摘要： The present invention provides vectors that contain and co-express in vivo or in vitro immunogenic polypeptides or antigens together with an OX40L polypeptide, which functions as a genetic adjuvant. Together, the immunogenic polypeptide and the OX40L polypeptide elicit an immune response in animal or human, which is greater than the immune response elicited by the immunogenic polypeptide alone. In a particular example, the invention provides vectors encoding a Rabies G immunogenic polypeptide and a canine OX40L genetic adjuvant, which vectors elicit strong immune responses in canine against rabies virus.

摘要翻译： 本发明提供载体，其含有体内或体外免疫原性多肽或抗原以及作为遗传佐剂起作用的OX40L多肽的载体。 一起，免疫原性多肽和OX40L多肽在动物或人体中引发免疫应答，其大于单独的免疫原性多肽引起的免疫应答。 在一个具体实例中，本发明提供了编码狂犬病G免疫原性多肽和犬OX40L遗传佐剂的载体，该载体在犬中针对狂犬病病毒引起强烈的免疫应答。

公开(公告)号：US09216213B2

公开(公告)日：2015-12-22

申请号：US13451667

申请日：2012-04-20

申请人： Joanne L. Maki ,  Tricia Lynn Fry ,  Jerome Cornelius Hurley ,  Lowell Allen Miller

发明人： Joanne L. Maki ,  Tricia Lynn Fry ,  Jerome Cornelius Hurley ,  Lowell Allen Miller

IPC分类号： A61K39/205 ,  A61P31/14 ,  A61K39/00 ,  C07K14/145 ,  C07K14/115 ,  A61K39/285 ,  C12N15/39 ,  C12N15/863 ,  A61K39/12 ,  A61K39/39

CPC分类号： A61K39/205 ,  A61K39/12 ,  A61K39/39 ,  A61K2039/5256 ,  A61K2039/542 ,  A61K2039/55583 ,  C07K14/145 ,  C12N2710/24111 ,  C12N2710/24141 ,  C12N2710/24143 ,  C12N2760/18034 ,  C12N2760/20134

摘要： The present invention relates to adjuvanted recombinant anti-rabies vaccines and the oral administration of such vaccines to raccoons and other wildlife. Advantageously, the anti-rabies vaccine may comprise a recombinant vaccinia virus containing a rabies glycoprotein gene. The invention encompasses methods of vaccinating raccoons and other wildlife by administration of an anti-rabies vaccines which may comprise a recombinant vaccinia virus containing a rabies glycoprotein gene, in combination with an adjuvant which increases both vaccine viscosity and efficacy. The invention provides effective oral recombinant vaccines used in oral rabies vaccination (ORV) programs for wildlife, effective at protecting raccoons, gray foxes, coyotes, and other animals.

摘要翻译： 本发明涉及佐剂化的重组抗狂犬病疫苗，并将这种疫苗口服给浣熊和其他野生动物。 有利地，抗狂犬病疫苗可以包含含有狂犬病糖蛋白基因的重组痘苗病毒。 本发明包括通过施用抗狂犬病疫苗接种浣熊疫苗和其他野生动物的方法，所述抗狂犬病疫苗可以包含含有狂犬病糖蛋白基因的重组痘苗病毒与佐剂组合，这增加了疫苗粘度和功效。 本发明提供了用于野生动物口服狂犬病疫苗接种（ORV）方案的有效的口服重组疫苗，有效地保护了浣熊，灰狐，土狼和其他动物。

公开(公告)号：US09149504B2

公开(公告)日：2015-10-06

申请号：US13328748

申请日：2011-12-16

申请人： David Terman

发明人： David Terman

IPC分类号： A61K48/00 ,  A61K38/16 ,  A61K39/00 ,  A61K39/085 ,  A61K45/06 ,  C12N15/86 ,  C12N15/863

CPC分类号： A61K38/164 ,  A61K39/0011 ,  A61K39/085 ,  A61K45/06 ,  A61K48/00 ,  A61K48/005 ,  C12N15/86 ,  C12N15/8636 ,  A61K2300/00

摘要： Herein we provide cDNA extracted from tumor cells, normal cells or treatment resistant tumor cells that have been transduced with virus capable of altering self and/or tumor associated antigens (VASTA) fused recombinantly to nucleic acids encoding wild type superantigens, superantigens, superantigen homologues and superantigen-tumor specific targeting molecules and further linked to a costimulatory molecule. The extracted cDNA is linked to a VASTA and delivered to tumor bearing hosts parenterally wherein they induce a tumoricidal response. These agents are also incorporated into a tumor tropic cell carrier for protected delivery to tumor.

摘要翻译： 在本文中，我们提供从肿瘤细胞，正常细胞或治疗抗性肿瘤细胞提取的cDNA，其已经用能够改变重组融合到编码野生型超级抗原，超级抗原，超抗原同源物的核酸的自身和/或肿瘤相关抗原（VASTA）的病毒转导， 超抗原 - 肿瘤特异性靶向分子，并进一步与共刺激分子连接。 将提取的cDNA连接到VASTA，并将其递送至胃肠外携带的宿主，其中它们诱导杀肿瘤反应。 这些试剂也掺入到转移癌细​​胞载体中以保护递送至肿瘤。